Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy

被引:25
作者
Lamarca, Angela [1 ]
Rigby, Christina [1 ]
McNamara, Mairead G. [1 ,2 ]
Hubner, Richard A. [1 ]
Valle, Juan W. [1 ,2 ]
机构
[1] Christie NHS Fdn Trust, Dept Med Oncol, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[2] Univ Manchester, Inst Canc Sci, Manchester Acad Hlth Sci Ctr, Manchester M20 4BX, Lancs, England
关键词
Advanced biliary tract cancer; Pancreatic cancer; Biliary obstruction; Biliary stent; Stent-related event; BILE-DUCT STONES; URSODEOXYCHOLIC ACID; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; PREVENTION; OCCLUSION; CIPROFLOXACIN; OBSTRUCTION; CANCER; MULTICENTER;
D O I
10.3748/wjg.v22.i26.6065
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: to determine the impact (morbidity/mortality) of biliary stent-related events (SRE) (cholangitis or stent obstruction) in chemotherapy-treated pancreaticobiliary patients. METHODS: All consecutive patients with advanced pancreatobiliary cancer and a biliary stent in-situ prior to starting palliative chemotherapy were identified retrospectively from local electronic case-note records (Jan 13 to Jan 15). The primary end-point was SRE rate and the time-to-SRE (defined as time from first stenting before chemotherapy to date of SRE). Progression-free survival and overall survival were measured from the time of starting chemotherapy. Kaplan-Meier, Cox and Fine-Gray regression (univariate and multivariable) analyses were employed, as appropriate. For the analysis of time-to-SRE, death was considered as a competing event. RESULTS: Ninety-six out of 693 screened patients were eligible; 89% had a metal stent (the remainder were plastic). The median time of follow-up was 9.6 mo (range 2.2 to 26.4). Forty-one patients (43%) developed a SRE during follow-up [cholangitis (39%), stent obstruction (29%), both (32%)]. There were no significant differences in baseline characteristics between the SRE group and no-SRE groups. Recorded SRE-consequences were: none (37%), chemotherapy delay (24%), discontinuation (17%) and death (22%). The median time-to-SRE was 4.4 mo (95% CI: 3.6-5.5). Patients with severe comorbidities (p < 0.001) and patients with >= 2 baseline stents/biliary procedures [HR = 2.3 (95% CI: 1.2-4.44), p = 0.010] had a shorter time-to-SRE on multivariable analysis. Stage was an independent prognostic factor for overall survival (p = 0.029) in the multivariable analysis adjusted for primary tumour site, performance status and development of SRE (SRE group vs no-SRE group). CONCLUSION: SREs are common and impact on patient's morbidity. Our results highlight the need for prospective studies exploring the role of prophylactic strategies to prevent/delay SREs.
引用
收藏
页码:6065 / 6075
页数:11
相关论文
共 32 条
[1]   SYMPTOM RELIEF AND QUALITY-OF-LIFE AFTER STENTING FOR MALIGNANT BILE-DUCT OBSTRUCTION [J].
BALLINGER, AB ;
MCHUGH, M ;
CATNACH, SM ;
ALSTEAD, EM ;
CLARK, ML .
GUT, 1994, 35 (04) :467-470
[2]   RANDOMIZED TRIAL OF PREVENTION OF BILIARY STENT OCCLUSION BY URSODEOXYCHOLIC ACID PLUS NORFLOXACIN [J].
BARRIOZ, T ;
INGRAND, P ;
BESSON, I ;
DELEDINGHEN, V ;
SILVAIN, C ;
BEAUCHANT, M .
LANCET, 1994, 344 (8922) :581-582
[3]   Managing malignant biliary obstruction in pancreas cancer: Choosing the appropriate strategy [J].
Boulay, Brian R. ;
Parepally, Mayur .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (28) :9345-9353
[4]   The role of ciprofloxacin in prolonging polyethylene biliary stent patency: A MultiCenter, double-blinded effectiveness study [J].
Chan, G ;
Barkun, JE ;
Barkun, AN ;
Valois, E ;
Cohen, A ;
Friedman, G ;
Parent, J ;
Love, YJ ;
Enns, R ;
Baffis, V ;
Jabbari, M ;
Szego, P ;
Stein, L ;
Abraham, N .
JOURNAL OF GASTROINTESTINAL SURGERY, 2005, 9 (04) :481-488
[5]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[6]   Hydrophilic hydromer-coated polyurethane stents versus uncoated stents in malignant biliary obstruction: a randomized trial [J].
Costamagna, G ;
Mutignani, M ;
Rotondano, G ;
Cipolletta, L ;
Ghezzo, L ;
Foco, A ;
Zambelli, A .
GASTROINTESTINAL ENDOSCOPY, 2000, 51 (01) :8-11
[7]   RANDOMIZED TRIAL OF SELF-EXPANDING METAL STENTS VERSUS POLYETHYLENE STENTS FOR DISTAL MALIGNANT BILIARY OBSTRUCTION [J].
DAVIDS, PHP ;
GROEN, AK ;
RAUWS, EAJ ;
TYTGAT, GNJ ;
HUIBREGTSE, K .
LANCET, 1992, 340 (8834-5) :1488-1492
[8]   Prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin -: A multicenter randomized trial [J].
De Lédinghen, V ;
Person, B ;
Legoux, JL ;
Le Sidaner, A ;
Desaint, B ;
Greff, M ;
Moesch, C ;
Grollier, G ;
Ingrand, P ;
Sautereau, D ;
Beauchant, M .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (01) :145-150
[9]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[10]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247